氰基丙烯酸酯胶与射频消融治疗CEAP 6级患者浅静脉反流的比较
本研究多机构回顾性比较了CEAP 6级患者接受ClosureFast射频消融(RFA)与VenaSeal氰基丙烯酸酯胶闭合的伤口愈合情况,共纳入119例患者(RFA 68肢,VenaSeal 51肢)。VenaSeal组伤口愈合中位时间显著短于RFA组(43天 vs 104天,P=.001),且按溃疡大小分层后VenaSeal仍愈合更快。两种方法均安全有效,治疗方式是伤口愈合时间的唯一显著预测因素。
要点
- VenaSeal组伤口愈合中位时间显著短于RFA组(43天 vs 104天,P=.001)。
- 按溃疡大小(<3 cm²或>3 cm²)分层后,VenaSeal愈合速度仍显著更快。
- 两组溃疡复发率无显著差异(RFA 22.1% vs VenaSeal 13.7%,P=.25)。
核心结论
- ClosureFast RFA和VenaSeal均为消除主干静脉功能不全的安全有效方法。
- VenaSeal在大型和小型溃疡中均显示出优于ClosureFast的伤口愈合时间。
研究设计与样本
- 多机构回顾性研究,纳入2015至2020年接受主干静脉闭合的CEAP 6级患者。
- 共119例患者(119肢),RFA组68肢,VenaSeal组51肢。
- 中位随访105天(四分位距44-208天)。
主要发现
- VenaSeal组伤口愈合中位时间显著短于RFA组(43天 vs 104天,P=.001)。
- RFA组深静脉血栓史比例显著更高(29% vs 10%,P=.01),深静脉反流比例也更高(82% vs 51%,P=.003)。
- VenaSeal组年龄更大(72岁 vs 65岁,P=.02),冠状动脉疾病比例更高(37% vs 16%,P=.01)。
- RFA组有2例发生术后感染。
- 溃疡复发率RFA组22.1%,VenaSeal组13.7%(P=.25)。
关键数值与推荐
- 按溃疡大小分层:小溃疡<3 cm²,大溃疡>3 cm²。
- VenaSeal组伤口愈合中位时间43天,RFA组104天(P=.001)。
- 溃疡复发率RFA组22.1%,VenaSeal组13.7%(P=.25)。
- RFA组深静脉血栓史29%,VenaSeal组10%(P=.01)。
- RFA组深静脉反流82%,VenaSeal组51%(P=.003)。
临床怎么用
- 对于CEAP 6级静脉性溃疡患者,VenaSeal可能缩短伤口愈合时间,尤其适用于大溃疡。
- 选择RFA或VenaSeal时需考虑患者深静脉血栓史、深静脉反流及合并症情况。
- 两种方法均可安全用于消除主干静脉功能不全,术后感染和复发风险需监测。
局限性
- 回顾性研究设计,存在选择偏倚。
- 两组基线特征存在显著差异(如深静脉血栓史、深静脉反流、年龄、冠心病比例)。
- 样本量较小(共119例),随访时间有限(中位105天)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Venous leg ulcers (CEAP [clinical, etiologic, anatomic, pathophysiologic] class 6) represent the most severe form of chronic venous insufficiency. As closure techniques for superficial venous reflux evolve, direct outcome comparisons of treatments are integral, because many studies have already demonstrated that early endovenous intervention improves wound healing. The present study compared the rates of venous wound healing between two techniques of superficial vein closure: ClosureFast radiofrequency ablation (RFA) and adhesive closure (VenaSeal; both Medtronic, Inc, Minneapolis, Minn). METHODS: We performed a multi-institutional retrospective review of all patients with CEAP class 6 who had undergone closure of their truncal veins from 2015 to 2020. Patients undergoing ClosureFast RFA were compared with those undergoing VenaSeal adhesive closure. The primary endpoint was the interval to wound healing from initial vein closure. The secondary endpoints included ulcer recurrence and infection rates. Bivariate analysis involved the χ2, Fisher exact, t, and Wilcoxon rank sum tests. Multivariate linear regression analysis was used to examine the factors affecting the time to wound healing in the most predictive model. Statistical significance was defined as P < .05. RESULTS: A total of 119 patients with CEAP 6 were included, with a median follow-up of 105 days (interquartile range, 44-208 days). Of the 119 limbs, 68 were treated with RFA and 51 with VenaSeal. Significantly more patients undergoing RFA had had a history of deep vein thrombosis (29% vs 10%; P = .01) and deep venous reflux (82% vs 51%; P = .003). The VenaSeal patients were older (72 years vs 65 years; P = .02) with a greater rate of coronary artery disease (16% vs 37%; P = .01). The median time to wound healing after the procedure was significantly shorter for VenaSeal than for RFA (43 vs 104 days; P = .001). Two RFA patients developed a postprocedure infection. The ulcer recurrence rate was 19.3% (22.1% for RFA vs 13.7% for VenaSeal; P = .25). On multivariate analysis, the treatment modality was the only significant predictor of the time to wound healing. When stratified by ulcer size as small (<3 cm2) vs large (>3 cm2), VenaSeal closure healed the wounds significantly faster for all ulcers. CONCLUSIONS: ClosureFast and VenaSeal are both safe and effective treatments to eliminate truncal venous insufficiency. VenaSeal showed a superior time to wound healing compared with ClosureFast in both large and small ulcers.
引用
- O'Banion LA, Reynolds KB, Kochubey M, et al. A comparison of cyanoacrylate glue and radiofrequency ablation techniques in the treatment of superficial venous reflux in CEAP 6 patients. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33453440. doi:10.1016/j.jvsv.2020.12.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。